Related Experiment Video
Updated: Mar 26, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Cancer stem cells and personalized cancer nanomedicine
Petra Gener1,2, Diana Fernandes de Sousa Rafael1,3, Yolanda Fernández1,2,4
1Drug Delivery & Targeting Group; CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Abstract:
Despite the progress in cancer treatment over the past years advanced cancer is still an incurable disease. Special attention is pointed toward cancer stem cell (CSC)-targeted therapies, because this minor cell population is responsible for the treatment resistance, metastatic growth and tumor recurrence. The recently described CSC dynamic phenotype and interconversion model of cancer growth hamper even more the possible success of current cancer treatments in advanced cancer stages. Accordingly, CSCs can be generated through dedifferentiation processes from non-CSCs, in particular, when CSC populations are depleted after treatment. In this context, the use of targeted CSC nanomedicines should be considered as a promising tool to increase CSC sensitivity and efficacy of specific anti-CSC therapies.
Insights
Targeting cancer stem cells (CSCs) is crucial for treating advanced cancers. Nanomedicines offer a promising approach to enhance CSC-targeted therapies and overcome treatment resistance.
Area of Science:
- Oncology
- Nanomedicine
- Cancer Biology
Background:
- Advanced cancer remains largely incurable despite therapeutic progress.
- Cancer stem cells (CSCs) drive treatment resistance, metastasis, and recurrence.
- The dynamic CSC phenotype and interconversion model complicate treatment strategies.
Purpose of the Study:
- To explore the potential of CSC-targeted nanomedicines.
- To enhance the efficacy of anti-CSC therapies.
- To address challenges posed by CSCs in advanced cancer treatment.
Main Methods:
- Review of current literature on CSCs and nanomedicine.
- Analysis of CSC dynamic phenotype and interconversion models.
- Evaluation of nanomedicine strategies for CSC targeting.
Main Results:
- CSCs are a key factor in advanced cancer progression and treatment failure.
- Dedifferentiation of non-CSCs can generate CSCs, especially after treatment.
- Targeted nanomedicines show potential for increasing CSC sensitivity.
Conclusions:
- Targeted nanomedicines represent a promising strategy for overcoming CSC-mediated resistance.
- Enhancing CSC sensitivity is vital for improving advanced cancer treatment outcomes.
- Further research into CSC-targeted nanomedicines is warranted.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:40Cancer Stem Cells and Tumor Maintenance
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
02:18Cancer
02:57Targeted Cancer Therapies